Show simple item record

dc.contributor.authorHendrickson, Ronald C.
dc.contributor.authorLee, Anita Y.H.
dc.contributor.authorSong, Qinghua
dc.contributor.authorLiaw, Andy
dc.contributor.authorWiner, Matt
dc.contributor.authorPaweletz, Cloud P.
dc.contributor.authorSeeburger, Jeffrey L.
dc.contributor.authorLi, Jenny
dc.contributor.authorMeng, Fanyu
dc.contributor.authorDeyanova, Ekaterina G.
dc.contributor.authorMazur, Matthew T.
dc.contributor.authorSettlage, Robert E.
dc.contributor.authorZhao, Xuemei
dc.contributor.authorSouthwick, Katie
dc.contributor.authorDu, Yi
dc.contributor.authorHolder, Dan
dc.contributor.authorSachs, Jeffrey R.
dc.contributor.authorLaterza, Omar F.
dc.contributor.authorDallob, Aimee
dc.contributor.authorChappell, Derek L.
dc.contributor.authorSnyder, Karen
dc.contributor.authorModur, Vijay
dc.contributor.authorKing, Elizabeth
dc.contributor.authorJoachim, Catharine
dc.contributor.authorBondarenko, Andrey Y.
dc.contributor.authorShearman, Mark
dc.contributor.authorSoper, Keith A.
dc.contributor.authorSmith, A. David
dc.contributor.authorPotter, William Z.
dc.contributor.authorKoblan, Ken S.
dc.contributor.authorSachs, Alan B.
dc.contributor.authorYates, Nathan A.
dc.date.accessioned2017-11-02T13:12:32Z
dc.date.available2017-11-02T13:12:32Z
dc.date.issued2015-08-13
dc.identifier.urihttp://hdl.handle.net/10919/79914
dc.description.abstractDisease modifying treatments for Alzheimer’s disease (AD) constitute a major goal in medicine. Current trends suggest that biomarkers reflective of AD neuropathology and modifiable by treatment would provide supportive evidence for disease modification. Nevertheless, a lack of quantitative tools to assess disease modifying treatment effects remains a major hurdle. Cerebrospinal fluid (CSF) biochemical markers such as total tau, p-tau and Ab42 are well established markers of AD; however, global quantitative biochemical changes in CSF in AD disease progression remain largely uncharacterized. Here we applied a high resolution open discovery platform, dMS, to profile a cross-sectional cohort of lumbar CSF from post-mortem diagnosed AD patients versus those from non-AD/non-demented (control) patients. Multiple markers were identified to be statistically significant in the cohort tested. We selected two markers SME-1 (p<0.0001) and SME-2 (p = 0.0004) for evaluation in a second independent longitudinal cohort of human CSF from post-mortem diagnosed AD patients and age-matched and case-matched control patients. In cohort-2, SME-1, identified as neuronal secretory protein VGF, and SME-2, identified as neuronal pentraxin receptor-1 (NPTXR), in AD were 21% (p = 0.039) and 17% (p = 0.026) lower, at baseline, respectively, than in controls. Linear mixed model analysis in the longitudinal cohort estimate a decrease in the levels of VGF and NPTXR at the rate of 10.9% and 6.9% per year in the AD patients, whereas both markers increased in controls. Because these markers are detected by mass spectrometry without the need for antibody reagents, targeted MS based assays provide a clear translation path for evaluating selected AD disease-progression markers with high analytical precision in the clinic.en_US
dc.description.sponsorshipThis discovery proteomics and analysis work was supported by Merck & Co.en_US
dc.language.isoen_USen_US
dc.publisherPLOSen_US
dc.titleHigh Resolution Discovery Proteomics Reveals Candidate Disease Progression Markers of Alzheimer’s Disease in Human Cerebrospinal Fluiden_US
dc.typeArticleen_US
dc.title.serialPLoS ONEen_US
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0135365
dc.identifier.volume10en_US
dc.identifier.issue8en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record